Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2012-10-408021PMID 23315167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• b -Thalassemia Intermedia: A Clinical Perspective

  2012cited by this paper
• Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea

  2012cited by this paper
• β-thalassemia intermedia: a clinical perspective.

  2012cited by this paper
• Contemporary approaches to treatment of beta-thalassemia intermedia.

  2012cited by this paper
• Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

  2012cited by this paper
• Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia.

  2012cited by this paper
• Advances in the treatment of alpha-thalassemia.

  2012cited by this paper
• The definition and epidemiology of non-transfusion-dependent thalassemia.

  2012cited by this paper
• Treatment strategies for hemoglobin E beta-thalassemia.

  2012cited by this paper
• Cerebral infarction in β-thalassemia intermedia: breaking the silence.

  2012cited by this paper
• A phase 1/2 trial of HQK‐1001, an oral fetal globin inducer, in sickle cell disease

  2012cited by this paper
• Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion

  2012cited by this paper
• The XmnI and BCL11A Single Nucleotide Polymorphisms May Help Predict Hydroxyurea Response in Iranian β-Thalassemia Patients

  2012cited by this paper
• Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.

  2011cited by this paper
• MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13

  2011cited by this paper
• Interactions Of Hydroxycarbamide (Hydroxyurea) With Iron And Copper: Implications On Toxicity and Therapeutic Strategies

  2011cited by this paper
• Darbepoetin alfa for the treatment of anaemia in alpha‐ or beta‐ thalassaemia intermedia syndromes

  2011cited by this paper
• Targeted therapeutic strategies for fetal hemoglobin induction.

  2011influential reference
• Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran

  2011influential reference
• A pilot study of subcutaneous decitabine in β-thalassemia intermedia.

  2011cited by this paper
• Comparative study of pulmonary circulation and myocardial function in patients with β‐thalassemia intermedia with and without hydroxyurea, a case–control study

  2011cited by this paper
• Thrombosis in Thalassemia: Why are we so Concerned?

  2011cited by this paper
• Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

  2011influential reference
• Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management

  2011cited by this paper
• Efficacy of Hydroxyurea in Providing Transfusion Independence in &bgr;-Thalassemia

  2011cited by this paper
• Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease

  2011cited by this paper
• KLF1 regulates BCL11A expression and γ- to β-globin gene switching

  2010cited by this paper
• Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

  2010influential reference
• Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.

  2010cited by this paper
• Beta-thalassemia

  2010influential reference
• Haploinsufficiency for the erythroid transcription factor KLF1 causes Hereditary Persistence of Fetal Hemoglobin

  2010cited by this paper
• Thalassemia: an overview of 50 years of clinical research.

  2010influential reference
• Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-β-thalassaemia: a genotypic and phenotypic study

  2010influential reference
• Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.

  2010influential reference
• How I use hydroxyurea to treat young patients with sickle cell anemia.

  2010influential reference
• Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia

  2010cited by this paper
• Effect of combination therapy of hydroxyurea with l‐carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with β‐thalassemia intermedia

  2010cited by this paper
• Adaptation to anemia in hemoglobin E-ß thalassemia.

  2010cited by this paper
• Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

  2010influential reference
• Age‐related complications in treatment‐naïve patients with thalassaemia intermedia

  2010cited by this paper
• ADVERSE EFFECTS OF HYDROXYUREA IN β-THALASSEMIA INTERMEDIA PATIENTS: 10 Years’ Experience

  2010influential reference
• Echocardiographic finding in beta‐thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta‐thalassemia intermedia

  2009cited by this paper
• Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.

  2009influential reference
• HYDROXYUREA-INDUCED HEMATOLOGICAL RESPONSE IN TRANSFUSION-INDEPENDENT BETA-THALASSEMIA INTERMEDIA: Case Series and Review of Literature

  2009cited by this paper
• Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.

  2009cited by this paper
• Amelioration of Sardinian beta0 thalassemia by genetic modifiers.

  2009cited by this paper
• Hydroxyurea therapy in 49 patients with major beta-thalassemia.

  2009cited by this paper
• A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E

  2009cited by this paper
• Hydroxycarbamide‐induced changes in E/beta thalassemia red blood cells

  2008cited by this paper
• Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia

  2008cited by this paper
• A scoring system for the classification of β‐thalassemia/Hb E disease severity

  2008cited by this paper
• Induction of gamma‐globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients

  2008cited by this paper
• human erythroid cells Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in

  2008cited by this paper
• Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.

  2008cited by this paper
• A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger.

  2008cited by this paper
• Thalidomide therapy in a patient with thalassemia major.

  2008cited by this paper
• Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.

  2008cited by this paper
• Guidelines for the Clinical Management of Thalassaemia

  2008cited by this paper
• Response to hydroxyurea therapy in β‐thalassemia

  2008cited by this paper
• Clinical effectiveness of decitabine in severe sickle cell disease

  2008cited by this paper
• Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A

  2008cited by this paper
• β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability

  2007influential reference
• Efficacy of Hydroxyurea (HU) in Reduction of Pack Red Cell (PRC) Transfusion Requirement Among Children Having Beta-thalassemia Major: Karachi HU Trial (KHUT)

  2007cited by this paper
• Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia

  2007cited by this paper
• The thalassaemia syndromes

  2007influential reference
• Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin.

  2007cited by this paper
• A Review of Cis-Trans Interplay Between DNA Sequences 5′ to the Gγ- and β-Globin Genes Among Hb F-Malta-I Heterozygotes/Homozygotes and β-Thalassemia Homozygotes/Compound Heterozygotes, and the Effects of Hydroxyurea on the Hb F/F-Erythrocyte; the Need for Large Multicenter Trials

  2007cited by this paper
• Age-related changes in adaptation to severe anemia in childhood in developing countries

  2007cited by this paper
• Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia.

  2006cited by this paper
• Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long‐term follow up

  2006cited by this paper
• cMYB is involved in the regulation of fetal hemoglobin production in adults.

  2006cited by this paper
• The myeloproliferative disorders.

  2006cited by this paper
• Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients’ peripheral blood erythroid cell culture

  2006cited by this paper
• Gene Expression (1086 articles)

  2006cited by this paper
• Use of virostatics as a means of targeting human immunodeficiency virus infection.

  2006cited by this paper
• Beta-thalassemia.

  2005cited by this paper
• In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.

  2005cited by this paper
• Hydroxyurea in thalassemia intermedia—a promising therapy

  2005influential reference
• Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome

  2005cited by this paper
• Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran

  2005cited by this paper
• Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

  2005cited by this paper
• MEDICAL PROGRESS : β-thalassemia

  2005cited by this paper
• Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

  2004cited by this paper
• Treatment of β-Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules

  2004cited by this paper
• Cutaneous Adverse Reactions to Hydroxyurea in Patients with Intermediate Thalassemia

  2004cited by this paper
• Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening

  2004cited by this paper
• Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications.

  2004cited by this paper
• Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

  2003cited by this paper
• Long‐term hydroxyurea therapy in beta‐thalassaemia patients

  2003cited by this paper
• Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.

  2003cited by this paper
• Flow Cytometric Analysis of Hydroxyurea Effects on Fetal Hemoglobin Production in Cultures of β‐Thalassemia Erythroid Precursors

  2003cited by this paper
• Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

  2003cited by this paper
• Esthesioneuroblastoma in children.

  2002cited by this paper
• Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

  2002cited by this paper
• Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway.

  2001cited by this paper
• HYDROXYUREA PROMOTES THE REDUCTION OF SPONTANEOUS BFU-e TO NORMAL LEVELS IN SS AND S/β THALASSEMIC PATIENTS

  2001cited by this paper
• Effects of hydroxurea, stem cell factor, and erythropoietin in combination on fetal hemoglobin in the baboon.

  2001cited by this paper
• Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia.

  2001cited by this paper
• Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management

  2001cited by this paper
• CLINICAL AND HEMATOLOGICAL RESPONSES TO HYDROXYUREA IN SICILIAN PATIENTS WITH Hb S/β-THALASSEMIA

  2001cited by this paper

• Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells

  2026cites this paper
• Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.

  2026cites this paper
• Efficacy and safety of luspatercept in non–transfusion-dependent β-thalassemia: long-term results from the BEYOND study

  2025cites this paper
• Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis

  2025cites this paper
• Correlation between Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin Concentration, and Fetal Hemoglobin Levels in Sickle Cell Anemia Patients of Saurashtra Region in Gujarat

  2025cites this paper
• Thalassemia in Bangladesh: progress, challenges, and a strategic blueprint for prevention

  2025cites this paper
• Non‐Transfusion‐Dependent Thalassemia: An Image Gallery Worth a Thousand Words

  2025cites this paper
• Impact of lifetime anaemia and iron control on outcomes in β‐thalassaemia: Data from the longitudinal de‐LIGHT study

  2025cites this paper
• Progress and prospect of minicircle as a minimized non-viral DNA vector in gene therapy and regenerative medicine

  2025cites this paper
• Cellular and molecular targets in β-Thalassemia: advances in iron Regulation, Erythropoiesis, and Gene-Based therapies

  2025cites this paper
• A critique review of fetal hemoglobin modulators through targeting epigenetic regulators for the treatment of sickle cell disease.

  2025cites this paper
• Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?

  2025cites this paper
• Upregulation of miR-17-3p is associated with HbF in patients with β-thalassemia and induces γ-globin expression by targeting BCL11A

  2025cites this paper
• Effects of Thalidomide on Metabolism and Lifespan of Red Blood Cell in Patients With β-Thalassemia Major: A Post Hoc Analysis of a Randomized Controlled Trial.

  2025cites this paper
• Medical management of thalassaemia: Pushing boundaries with limited resources

  2025cites this paper
• Genotypic and hematologic association of pulmonary hypertension in non-transfusion-dependent thalassemia

  2025cites this paper
• Thalassemias in Manipur, India

  2025cites this paper
• Hemoglobin Richmond Masquerading as Fetal Hemoglobin in a Child With Sickle Cell Disease: A Case Report and Review of the Literature

  2025cites this paper
• Hydroxyurea achieved a hematologic response in a patient with β‐thalassemia and secondary severe thrombocytosis post splenectomy

  2024cites this paper
• The effect of aqueous extract of Iranian oak (Quercus brantii) on antioxidant capacity and oxidative stress in beta-thalassemia patients: Randomized controlled trial.

  2024cites this paper
• A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds

  2024cites this paper
• The role of miR-129-5p in regulating γ-globin expression and erythropoiesis in β-thalassemia.

  2024cites this paper
• Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat

  2024cites this paper
• Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for β-thalassemia.

  2024cites this paper
• Maximizing longevity: erythropoietin’s impact on sickle cell anaemia survival rates

  2024cites this paper
• Effects of Thalidomide on Erythropoiesis and Iron Homeostasis in Transfusion-Dependent β-Thalassemia

  2024cites this paper
• The Effect of Resveratrol on Gamma Globin Gene Expression in Patients with Beta Thalassemia: The Role of Adaptation to Cellular Stress

  2024cites this paper
• Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life

  2024cites this paper
• Secondary amenorrhea in a β‐thalassemia major patient treated with thalidomide

  2024cites this paper
• Evaluating the Role of Red Blood Cell Lifespan in Transfusion‐Dependent β‐Thalassemia and Impact of Thalidomide Treatment

  2024cites this paper
• Point-of-care detection of hydroxyurea drug in serum using a supramolecular enzyme mimetic

  2024cites this paper
• Comparison of Efficacy and Safety of Thalidomide vs Hydroxyurea in Thalassemia Patients: A Single-Centre Pilot Study

  2024cites this paper
• Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience

  2024cites this paper
• Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.

  2024cites this paper
• Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

  2024cites this paper
• How I treat non-transfusion-dependent β-thalassemia

  2023cites this paper
• Long‐term efficacy and safety of thalidomide treatment in children with β$\ubeta$ ‐thalassemia major

  2023cites this paper
• Review of endocrine complications in transfusion-dependent thalassemia

  2023cites this paper
• Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.

  2023cites this paper
• Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.

  2023cites this paper
• Fetal Hemoglobin Regulation in Beta-Thalassemia.

  2023cites this paper
• Nutritional studies in patients with β-thalassemia major: A short review

  2023cites this paper
• Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy

  2023cites this paper
• MUTATION ANALYSIS OF β -THALASSEMIA IN PATIENTS AT TERTIARY CARE: AN INITIAL PERSPECTIVE

  2023cites this paper
• Diagnostik und Therapie der alpha- und beta-Thalassämien

  2023cites this paper
• Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients

  2023cites this paper
• Gene Therapy for Hemoglobinopathies

  2023cites this paper
• Thalidomide‐associated autoimmune hemolytic anemia

  2022cites this paper
• Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm

  2022cites this paper
• Calorimetric Characterisation of the Binding Reaction Between Human Ferric Haemoglobins and Haptoglobin to Develop a Drug for Removal of Cell-Free Haemoglobin.

  2022cites this paper
• IVS I-5 (G > C) is associated with changes to the RBC membrane lipidome in response to hydroxyurea treatment in β-thalassemia patients.

  2022cites this paper
• Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

  2022cites this paper
• Treatment with Hydroxyurea Leads to Fetal Hemoglobin Reactivation through CA1 and LIN28B Genes: An In Vitro Study

  2022cites this paper
• Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective

  2022cites this paper
• Impact of Hydroxyurea on Blood Transfusion Rate in Patients of Beta-Thalassemia Major

  2022cites this paper
• LRF Promotes Indirectly Advantageous Chromatin Conformation via BGLT3-lncRNA Expression and Switch from Fetal to Adult Hemoglobin

  2022cites this paper
• Diagnostik und Therapie der alpha- und beta-Thalassämien

  2022cites this paper
• In Vitro and In Vivo Studies for the Investigation of γ-Globin Gene Induction by Adhatoda vasica: A Pre-Clinical Study of HbF Inducers for β-Thalassemia

  2022cites this paper
• The use of hydroxyurea in the real life of MIOT network: an observational study

  2022cites this paper
• Non-Transfusion-Dependent Thalassemia: A Panoramic Review

  2022influential citation
• Quantification of human embryonic ζ-globin chains in Southeast Asian deletion (--SEA) carriers

  2022cites this paper
• Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies

  2021cites this paper
• First Aid Training to School Students: Should Younger Children Be Trained?

  2021cites this paper
• Safety: A Primary Concern in Thalidomide Use in Thalassemia

  2021cites this paper
• Anemia

  2021cites this paper
• Thalassemias: From gene to therapy.

  2021cites this paper
• Safety: A Primary Concern in Thalidomide Use in Thalassemia

  2021cites this paper
• 2021 update on clinical trials in β‐thalassemia

  2021cites this paper
• A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

  2021cites this paper
• A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic

  2021cites this paper
• A narrative review: the role of DOCK2 in immune-related diseases, hematopoietic or vascular diseases and solid tumor

  2021cites this paper
• Genome-based therapeutic interventions for β-type hemoglobinopathies

  2021cites this paper
• Lysine-specific histone demethylase 1 inhibition enhances robust fetal hemoglobin induction in human β0-thalassemia/hemoglobin E erythroid cells

  2021cites this paper
• Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience

  2021cites this paper
• COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation

  2020cites this paper
• UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells

  2020cites this paper
• Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia

  2020cites this paper
• Thalassemias

  2020cites this paper
• Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion dependent beta thalassaemias

  2020cites this paper
• Thalidomide for Patients with β-Thalassemia: A Multicenter Experience

  2020cites this paper
• Beta Thalassemia Major: Overview of Molecular Etiology, Pathophysiology, Current and Novel Therapeutic Approaches

  2020cites this paper
• Thalassemia Major and Intermedia Patients in East Java do not Show Fetal Hemoglobin Level Difference in Relation to XMNI Polymorphism

  2020influential citation
• Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients

  2020cites this paper
• Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins

  2020cites this paper
• Emerging therapies in β-thalassemia: toward a new era in management

  2020cites this paper
• Embryonic and Fetal Human Hemoglobins: Structures, Oxygen Binding, and Physiological Roles.

  2020cites this paper
• Blood supply challenges and transfusion care of patients with hemoglobinopathies during COVID19 pandemic

  2020cites this paper
• High‐level induction of fetal haemoglobin by pomalidomide in β‐thalassaemia/HbE erythroid progenitor cells

  2020cites this paper
• Natural compounds with the capacity to reactivate the gene of gamma-globin and induction of fetal hemoglobin - In vitro test

  2020influential citation
• The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.

  2020cites this paper
• Thromboembolism in Beta-Thalassemia Disease

  2019cites this paper
• Thalassemia: Common Clinical Queries in Management

  2019cites this paper
• Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia

  2019cites this paper
• Challenges of blood transfusions in β-thalassemia.

  2019cites this paper
• Cinchona alkaloids as natural fetal hemoglobin inducing agents in human erythroleukemia cells

  2019cites this paper
• Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies.

  2019cites this paper
• Recognition and Separation of Hemoglobin Variants via Molecularly Imprinted Polymers

  2019cites this paper
• Phenotypic-screening generates active novel fetal globin-inducers that downregulate Bcl11a in a monkey model.

  2019cites this paper
• Reflection of treatment proficiency of hydroxyurea treated β-thalassemia serum samples through nuclear magnetic resonance based metabonomics

  2019cites this paper
• Oridonin enhances γ‑globin expression in erythroid precursors from patients with β‑thalassemia via activation of p38 MAPK signaling.

  2019cites this paper